BELLUS Health Inc 뉴스 - BLU | 주식 토론토 증권거래소 | ADVFN

다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

BELLUS Health Inc (BLU)

19.48

0.00

( 0.00% )

업데이트: 09:00:00

개인 투자자를 위한 전문가급 도구.

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel...

BELLUS Santé participera prochainement à plusieurs conférences pour les investisseurs

BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe...

BELLUS Santé participera à la Cowen & Co. 42nd Annual Health Care Conference

BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe...

BELLUS Santé annonce ses résultats financiers et faits saillants pour l’exercice 2021

- Annonce des résultats principaux positifs de l’essai clinique SOOTHE de phase 2b pour le traitement de la toux chronique réfractaire qui...

BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States

BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced...

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

Common Shares Priced at US$8.00 per Share In connection with its previously announced public offering of common shares in Canada and the United...

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement...

BELLUS Santé annonce les principaux résultats positifs de son essai SOOTHE de phase 2b du BLU-5937 pour le traitement de la toux chronique réfractaire

Le principal critère d’évaluation de l’efficacité est statistiquement significatif, une réduction de 34 % de la fréquence de toux sur une période...

mik1234

mik1234 4 년 전

it was a good day $$ BLU

Oliverjack

Oliverjack 4 년 전

insider bought 260k worth today monday 13th lol

Bottom Feedr

Bottom Feedr 4 년 전

Massive drop and ceo buys more! Hmmnnnn

Bottom Feedr

Bottom Feedr 4 년 전

Wake up sleepy head time to rock the market!

dalesio_98

dalesio_98 6 년 전

RichardSawars

RichardSawars 6 년 전

TrendTrade2016

TrendTrade2016 6 년 전

BLU.TO hot canadian bio

TrendTrade2016

TrendTrade2016 6 년 전

BLU is a beast!!

TrendTrade2016

TrendTrade2016 6 년 전

The BLU beast!!

TrendTrade2016

TrendTrade2016 6 년 전

put out a call on BLU.TO a monster bio play!!

xr_biotech_consult

xr_biotech_consult 8 년 전

happy to sold nearly 8000 during last days...only 4000 left for sale today.

xr_biotech_consult

xr_biotech_consult 8 년 전

2.99 weeeeEEEE°°

xr_biotech_consult

xr_biotech_consult 9 년 전

what shoud i say? 2.32 !!

xr_biotech_consult

xr_biotech_consult 9 년 전

xr_biotech_consult

xr_biotech_consult 9 년 전

yessss..new high..1.92

xr_biotech_consult

xr_biotech_consult 9 년 전

great Chart.. crushed 1,75 good sign. more will come

xr_biotech_consult

xr_biotech_consult 9 년 전

pivotal Phase 3 trail completed, top line results expected q2, fast track by FDA, rare desease, Long patent protection, Peak sales expected -1b ! ongoing Pipeline with rare deseases.. still great opportunity here

xr_biotech_consult

xr_biotech_consult 9 년 전

xr_biotech_consult

xr_biotech_consult 9 년 전

hrhr here weee goo

xr_biotech_consult

xr_biotech_consult 9 년 전

expected Prices per Patient per year 200-275 Thousand

xr_biotech_consult

xr_biotech_consult 9 년 전

Peak sales expected 600m - 1b
http://www.bellushealth.com/English/investors-and-news/presentations/default.aspx

xr_biotech_consult

xr_biotech_consult 9 년 전

xr_biotech_consult

xr_biotech_consult 10 년 전

will move up again

xr_biotech_consult

xr_biotech_consult 10 년 전

target 2.50 CAD

xr_biotech_consult

xr_biotech_consult 10 년 전

yea hell great, new high hunts new high

xr_biotech_consult

xr_biotech_consult 10 년 전

BLU out in the blue

xr_biotech_consult

xr_biotech_consult 11 년 전

waht did i told u

xr_biotech_consult

xr_biotech_consult 11 년 전

massive breakout will come here

EURONEXT CA INDEX4

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관